Sanegene Bio Funding: $110M Raised, Series B (2025)
Sanegene Bio is a Biotech company. It has raised $110M in total funding. Latest round: Series B. Backed by Sino Biopharm, Legend Capital, Vivo Capital.
Sanegene Bio funding overview
Sanegene Bio is a Biotech company. Sanegene Bio has raised $110M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in December 2025. The round record for Sanegene Bio runs through 2025; nothing later has been disclosed. Investors on record include Sino Biopharm, Legend Capital, Vivo Capital, Invus, SymBiosis, Guofa Capital and 8 others. 14 distinct backers are named across the disclosed rounds.
Sanegene Bio at a glance
Total raised
$110M
Latest round
Series B
Latest round date
December 2025
Industry
Biotech
Notable investors
Sino Biopharm, Legend Capital, Vivo Capital, Invus, SymBiosis, Guofa Capital, TruMed, Lake Bleu Capital
Frequently asked about Sanegene Bio funding
How much has Sanegene Bio raised?
Sanegene Bio has raised $110M in total disclosed funding across the rounds on record.
Who has invested in Sanegene Bio?
Sino Biopharm, Legend Capital, Vivo Capital, Invus, SymBiosis, Guofa Capital are named among the investors backing Sanegene Bio.
What was the latest Sanegene Bio funding round?
The most recent disclosed round is a Series B, announced in December 2025.
Where is Sanegene Bio based?
No headquarters location is disclosed for Sanegene Bio.
What sector does Sanegene Bio operate in?
Sanegene Bio is tracked under Biotech, with $110M in disclosed funding.
When did Sanegene Bio last raise?
The last disclosed Sanegene Bio round closed in December 2025 at Series B.
Round data for Sanegene Bio is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the Biotech companies and backer lists below.
